Enlivex Completes Key Phase II Trial Milestone for Knee Osteoarthritis Treatment

Enlivex ( (ENLV) ) has shared an announcement.

On July 28, 2025, Enlivex Therapeutics announced that all 134 patients in its Phase II trial of Allocetra™ for moderate to severe knee osteoarthritis have completed a three-month follow-up, marking the primary timepoint for key endpoint measurements. The trial, which is double-blind and placebo-controlled, aims to evaluate the safety and efficacy of Allocetra™. The company plans to release audited topline results on August 18, 2025, which could significantly impact its operations and market positioning by providing insights into the treatment’s potential efficacy and safety, potentially guiding future development and stakeholder decisions.

The most recent analyst rating on (ENLV) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Spark’s Take on ENLV Stock

According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.

Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.

To see Spark’s full report on ENLV stock, click here.

More about Enlivex

Enlivex Therapeutics Ltd. is a clinical-stage company specializing in macrophage reprogramming immunotherapy. The company is focused on developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages to their homeostatic state, which is crucial for immune system rebalancing and addressing life-threatening and debilitating conditions.

Average Trading Volume: 81,576

Technical Sentiment Signal: Sell

Current Market Cap: $26.76M

Find detailed analytics on ENLV stock on TipRanks’ Stock Analysis page.